Pericarditis Market Report and Forecast 2025-2034

The pericarditis market size was valued at USD 2.44 Billion in 2024, driven by the rising prevalence of pericarditis across the 8 major markets. The market is expected to grow at a CAGR of 5.24% during the forecast period of 2025-2034, with the values likely to rise from USD 2.57 Billion in 2025 to USD 4.07 Billion by 2034.

Pericarditis Market Overview

Pericarditis is characterized by the inflammation of the pericardium (sac surrounding the heart) caused by various disorders such as myocardial infarction, infection, metabolic disorders, and tumors. Pericarditis is the most common pericardial disease, leading to 5.4-26 hospitalizations per 100,000 individuals annually in the United States. Recurrent pericarditis occurs in 30% of patients having acute pericarditis, with treatment lasting up to 7 years.  The rising prevalence of the disease is expected to augment the market size in the forecast period.

The surge in approvals from health regulatory agencies also drives the pericarditis market growth. In February 2024 , the United States Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to a small molecule drug candidate called CardiolRx™ to treat pericarditis. Developed by Cardiol Therapeutics Inc., a clinical-stage life sciences company in the United States, the drug candidate is undergoing Phase II clinical trials for recurrent pericarditis and acute myocarditis.

The emergence of novel therapies to treat the condition and address a wider section of patients is expected to fuel the market demand in coming years. Increased research and development initiatives along with investments made by the key players is projected to boost the market size. Heightened awareness of heart health among patients through campaigns and trends is another significant factor contributing to the increasing market size.

Pericarditis Market Trends

Rising Prevalence of Pericarditis

Pericarditis is increasingly prevalent, leading to a significant number of hospitalizations annually in the United States. Surge in cardiovascular issues, owing to fast paced, and sedentary lifestyles among individuals is a notable market trend.

Emergence of Novel Therapies

Innovative therapies are being developed and tested in clinical trials for the treatment of pericarditis. The introduction of novel treatment options is anticipated to meet the growing demand for effective management of the condition.

Increased Research and Development Investments

Key players in the healthcare industry are investing significantly in research and development activities aimed at advancing the understanding and treatment of pericarditis.

Heightened Awareness of Heart Health Among Patients

Growing awareness of heart health and cardiovascular diseases among patients is leading to early detection and diagnosis of pericarditis. This increased awareness supports the demand for pericarditis treatments.

Pericarditis Market Segmentation

The EMR’s report titled “Pericarditis Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Diagnostic Method:

• Electrocardiogram (ECG)
• Echocardiogram
• Computerized Tomography
• X-Ray
• Others

In terms of diagnostic methods, the market is segmented into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), and X-ray, among others. This segmentation ensures diagnosis and evaluation of pericarditis to facilitate appropriate treatment interventions.

Market Breakup by Drug Type:

• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Colchicine
• Others

Based on the drug type, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and others. NSAIDs are used to reduce inflammation and relieve pain associated with pericarditis. Colchicine has been effective in preventing recurrent pericarditis episodes.

Market Breakup by End User:

• Hospitals & Clinics
• Medical Institutes and Research Laboratories
• Others

Based on end users, the pericarditis market share is segmented hospitals and clinics, as well as medical institutes and research laboratories, among others.

Market Breakup by Distribution Channels:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Major distribution channels of the market include hospital pharmacies, retail pharmacies, online pharmacies, and others. Increasing digitization has led to increased preference for online pharmacies amongst patients.

Market Breakup by Region:

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

The market report includes 8 major markets projected to show significant growth in the forecast period. The segmentation based on the region covers the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America holds a high market value which can be attributed to the rising geriatric population base in the region. In addition, the presence of an advanced healthcare system and the increased prevalence of cardiovascular diseases are anticipated to propel the market growth.

Pericarditis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Kiniksa Pharmaceuticals
• Pfizer Inc.
• Bayer AG
• AstraZeneca Plc
• Sanofi
• Johnson and Johnson Services, Inc.
• Merck & Co., Inc.
• Allergan Plc.
• Novartis AG
• Perkin Elmer Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.